Skip to main content

rina-s

rina-s: 9 clinical trials tracked.

rina-s evidence translation

What we can confirm

9 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about rina-s, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (9)

Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment in Participants With Ovarian Cancer Following First-Line (1L) Platinum-Based Chemotherapy

NCT07859215Registry updated 2026-10-05·Phase 3
Not yet recruiting

Primary endpoint: Progression-free Survival (PFS), per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, as Determined by Blinded Independent Central Review (BICR)

InterventionalRandomizedopen602 targetStarted 2026-11Completion 2034-07Genmab

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

NCT07564141Registry updated 2026-10-07·Phase 3
Recruiting

Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)

InterventionalRandomizedopen688 targetStarted 2026-08Completion 2031-119 sites · Japan, United StatesGenmab

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

NCT07604766Registry updated 2026-10-06·Phase 3
Recruiting

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizedopen82 targetStarted 2026-06Completion 2028-1217 sites · ChinaGenmab

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

NCT07539311Registry updated 2026-10-06·Phase 2
Recruiting

Primary endpoint: Confirmed Objective Response Rate (ORR)

Interventionalopen160 targetStarted 2026-05Completion 2028-1117 sites · Australia, France, Japan, South Korea…Genmab

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

NCT07225270Registry updated 2026-10-06·Phase 3
Recruiting

Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, as Determined by Blinded Independent Central Review (BICR)

InterventionalRandomizedopen544 targetStarted 2026-04Completion 2030-0534 sites · Belgium, Finland, France, Japan…Genmab

A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer

NCT07288177Registry updated 2026-10-06·Phase 2
Recruiting

Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Investigator

Interventionalopen240 targetStarted 2026-01Completion 2028-1191 sites · Australia, Belgium, China, France…Genmab

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

NCT07166094Registry updated 2026-10-06·Phase 3
Recruiting

Primary endpoint: Progression-free Survival (PFS) per Response Criteria in Solid Tumors (RECIST) v1.1, as Determined by Blinded Independent Central Review (BICR)

InterventionalRandomizedopen660 targetStarted 2025-11Completion 2029-11177 sites · Australia, Belgium, Brazil, Canada…Genmab

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

NCT06619236Registry updated 2026-09-28·Phase 3
Active, not recruiting

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizedopen584 enrolledStarted 2025-02Completion 2027-1050 sites · United StatesGenmab

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

NCT05579366Registry updated 2026-10-07·Phase 1/Phase 2
Recruiting

Primary endpoint: Parts A, B, and D - Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]

Interventionalopen952 targetStarted 2022-12Completion 2027-1066 sites · China, Japan, United StatesGenmab